Premium
P4‐159: Screening and Recruitment Experience When Using Biomarker‐Based Population Definition in Alzheimer’s Disease Studies
Author(s) -
Smekens Pascale,
Mesens Sofie,
Engelborghs Sebastiaan,
Börjesson-Hanson Anne,
Christoph Laske,
Prins Niels D.,
Hugon Jacques,
Andreassen Niels,
Cuevas Jiméne Ana Isabel,
Timmers Maarten,
Tesseur Ina,
Van Nueten Luc,
Streffer Johannes
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2251
Subject(s) - medicine , biomarker , asymptomatic , dementia , disease , population , clinical trial , randomized controlled trial , memory clinic , oncology , biochemistry , chemistry , environmental health
no difference between groups in prior COPD diagnoses (11.1% vs. 9.1%, p1⁄4.71) and a trend towards a lower smoking history (25.0% vs. 42.8%, p1⁄4.05). Controlling for age and gender, abnormal FEV1/FVC ratios increased risk of poor cognitive performance (OR1⁄48.78; 2.4-31.8). Hippocampal volumes (R1⁄4.296, p1⁄4.03) and precuneus glucose metabolism (R1⁄4.286, p1⁄4.04) correlated with FEV1/FVC ratios. For every 0.5 difference between Lung Age/Chronological Age ratio, the MoCA reduced by 1 point (B1⁄4-0.55;T1⁄4-3.13,p1⁄4.002). Conclusions: The presence of COPD is associated with poorer cognitive performance and correlated with AD-related biomarkers (smaller hippocampal volumes, decreased precuneus glucose metabolism). Incorporating spirometry in the evaluation of older adults may help identify individuals at-risk for cognitive impairment.